Related Experiment Video

Updated: Jul 15, 2026

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice
07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

[Treatment of malignant pleural mesothelioma]

Toshikazu Yusa1

  • 1Chiba Pleural Tumor Study Group.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 14, 2007
PubMed

Insights

Malignant pleural mesothelioma has a poor prognosis, with a median survival of nine months. Pemetrexed combined with cisplatin shows promise as a future first-choice chemotherapy for this aggressive cancer.

Area of Science:

  • Oncology
  • Pulmonology

Context:

  • Mesothelioma incidence is rising in Japan.
  • Malignant pleural mesothelioma (MPM) accounts for 90% of mesothelioma cases.
  • MPM has a poor prognosis with a median survival of approximately nine months.

Purpose:

  • To review current and emerging treatment strategies for malignant pleural mesothelioma.
  • To highlight the efficacy of pemetrexed and cisplatin chemotherapy.

Summary:

  • Surgical options like extrapleural pneumonectomy or pleurectomy/decortication are available but often insufficient for a cure.
  • Multimodality treatment combining surgery with chemotherapy and/or radiotherapy is standard.
  • A phase III study confirmed the effectiveness of pemetrexed and cisplatin chemotherapy, positioning pemetrexed as a future first-line agent.
  • Investigational therapies include chemohyperthermia, cytokine treatments, angiogenesis inhibitors, gene therapy, and photodynamic therapy.

Impact:

  • Establishes pemetrexed-based chemotherapy as a key treatment for mesothelioma.
  • Underscores the urgent need for more effective mesothelioma treatment modalities.
  • Provides a comprehensive overview of therapeutic options for a challenging malignancy.

More Related Videos

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

Related Concept Videos

Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
Pleural Effusion II: Symptoms and Management01:28

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Pleura of the Lungs01:13

Pleura of the Lungs

The lungs are nestled in a cavity, shielded by the pleura. The pleura, a form of serous membrane, wraps around each lung. This membrane arrangement consists of two layers: the visceral and parietal pleurae. The visceral pleura lines the surface of the lungIn contrast, the parietal pleura is the outer layer and contacts to the thoracic wall, the mediastinum, and the diaphragm. The hilum is the point of connection between the visceral and parietal layers. The space between the parietal and...
Pneumothorax-II01:27

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...